A special protein can play a key role in the fight against certain types of prostate cancer. This is shown in a study by an international research group led from Umeå University, Sweden. Until now, ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).

Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...

Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine. The results ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...